[144] Fulgent Genetics, Inc. SEC Filing
Form 144 filed for Fulgent Genetics, Inc. (FLGT) reporting a proposed sale of 1,199 shares of common stock through Morgan Stanley Smith Barney on 08/27/2025 on NASDAQ with an aggregate market value of $25,760.20. The filing shows the shares to be sold were acquired as restricted stock that vested on 02/26/2024 as equity compensation, with 25,350 shares originally issued to the holder on that date. The issuer has 30,609,044 shares outstanding per the notice. The filer disclosed multiple prior open-market sales by the same person in the past three months totaling 3,704 shares with gross proceeds reported on specific dates. The signer certifies no undisclosed material information and acknowledges Rule 144/10b5-1 representations.
Deposito del Modulo 144 per Fulgent Genetics, Inc. (FLGT) che segnala la proposta di vendita di 1.199 azioni ordinarie tramite Morgan Stanley Smith Barney il 27/08/2025 sul NASDAQ per un valore di mercato complessivo di $25.760,20. La comunicazione indica che le azioni da vendere sono state acquisite come azioni vincolate convertite in proprietà il 26/02/2024 come compenso in azioni, con 25.350 azioni inizialmente assegnate al titolare in quella data. L'emittente risulta avere 30.609.044 azioni in circolazione secondo l'avviso. Il dichiarante ha riportato più vendite in open market effettuate dalla stessa persona negli ultimi tre mesi per un totale di 3.704 azioni, con proventi lordi indicati in date specifiche. Il firmatario certifica l'assenza di informazioni materiali non divulgate e conferma le dichiarazioni richieste dalla Regola 144/10b5-1.
Presentación del Formulario 144 para Fulgent Genetics, Inc. (FLGT) que informa una propuesta de venta de 1.199 acciones ordinarias a través de Morgan Stanley Smith Barney el 27/08/2025 en NASDAQ por un valor de mercado agregado de $25.760,20. El registro indica que las acciones a vender se adquirieron como acciones restringidas que vencieron el 26/02/2024 como compensación en acciones, con 25.350 acciones originalmente emitidas al titular en esa fecha. El emisor tiene 30.609.044 acciones en circulación según el aviso. El declarante divulgó múltiples ventas anteriores en el mercado abierto por la misma persona en los últimos tres meses, por un total de 3.704 acciones, con ingresos brutos reportados en fechas específicas. El firmante certifica que no existe información material no divulgada y reconoce las representaciones de la Regla 144/10b5-1.
Fulgent Genetics, Inc. (FLGT)에 대한 Form 144 제출로 NASDAQ에서 Morgan Stanley Smith Barney를 통해 2025-08-27에 1,199주의 보통주 매도를 제안했으며 총 시가가 $25,760.20로 보고되었습니다. 제출서류에 따르면 매도 예정 주식은 2024-02-26에 성과한 제한주(베스팅된 주식)로 주식 보상으로 취득되었고, 해당일에 보유자에게 총 25,350주가 원래 부여되었습니다. 발행회사는 통지서 기준으로 30,609,044주의 발행주식수가 있습니다. 제출자는 동일 인물에 의한 지난 3개월 내 다수의 기존 공개시장 매도를 총 3,704주로 공개했으며 특정 날짜에 대한 총수익이 보고되었습니다. 서명자는 미공개 중대한 정보가 없음을 인증하고 Rule 144/10b5-1 진술을 확인합니다.
Déclaration du Formulaire 144 pour Fulgent Genetics, Inc. (FLGT) signalant une proposition de vente de 1 199 actions ordinaires via Morgan Stanley Smith Barney le 27/08/2025 sur le NASDAQ pour une valeur de marché totale de 25 760,20 $. Le dossier indique que les actions à vendre ont été acquises en tant que actions restreintes ayant acquis le droit (vested) le 26/02/2024 en tant que rémunération en actions, 25 350 actions ayant été initialement attribuées au titulaire à cette date. L'émetteur compte 30 609 044 actions en circulation selon l'avis. Le déclarant a divulgué plusieurs ventes antérieures sur le marché ouvert par la même personne au cours des trois derniers mois pour un total de 3 704 actions, avec des produits bruts rapportés à des dates précises. Le signataire certifie l'absence d'informations matérielles non divulguées et reconnaît les déclarations requises par la règle 144/10b5-1.
Einreichung von Formular 144 für Fulgent Genetics, Inc. (FLGT), die einen geplanten Verkauf von 1.199 Aktien des Stammkapitals über Morgan Stanley Smith Barney am 27.08.2025 an der NASDAQ mit einem Gesamtmarktwert von $25.760,20 meldet. Die Einreichung gibt an, dass die zu verkaufenden Aktien als Restricted Stock, die am 26.02.2024 vested wurden, als Aktienvergütung erworben wurden; dem Inhaber wurden an diesem Datum ursprünglich 25.350 Aktien zugeteilt. Der Emittent hat laut Mitteilung 30.609.044 ausstehende Aktien. Der Meldende gab mehrere frühere Verkäufe am offenen Markt derselben Person in den vergangenen drei Monaten mit einer Gesamtsumme von 3.704 Aktien an, wobei Bruttoerlöse zu bestimmten Daten ausgewiesen wurden. Der Unterzeichner bestätigt, dass keine nicht offengelegten wesentlichen Informationen vorliegen, und erkennt die Angaben gemäß Regel 144/10b5-1 an.
- Insider disclosed sales transparently under Rule 144 with required details and certification of no undisclosed material information
- Securities to be sold were issued as restricted stock for services, indicating they derive from compensation rather than undisclosed purchases
- Proposed sale size is very small relative to the 30,609,044 shares outstanding, suggesting limited market impact
- Multiple recent sales by the same person in the past three months totaling 3,704 shares could reflect ongoing insider liquidity
- Filing lacks context on whether a 10b5-1 plan is in place (the form references the plan language but does not state a plan adoption date)
Insights
TL;DR: Routine insider share sales from vested equity; size is immaterial relative to outstanding shares.
The filing documents a proposed sale of 1,199 shares valued at $25,760 and prior sales totaling 3,704 shares in the trailing three months. These shares were granted as restricted stock that vested 02/26/2024 as equity compensation, indicating they are not open-market purchases but executive compensation liquidity events. At 30.6 million shares outstanding, the proposed sale represents a de minimis percentage of the float and is unlikely to affect valuation materially. The disclosure and Rule 144 certification are standard and reduce regulatory risk of the transaction.
TL;DR: Disclosure meets Rule 144 requirements; multiple recent sales warrant routine monitoring but show no obvious governance red flags.
The filer affirms no material nonpublic information and notes potential 10b5-1 plan representation. The securities originated from restricted stock vesting tied to services rendered, a common compensation mechanism. Multiple small sales by the same individual across May, June and August are disclosed with gross proceeds, which is appropriate transparency. Absent additional context (e.g., departures, related-party transactions), these filings align with typical insider liquidity and compliance practices.
Deposito del Modulo 144 per Fulgent Genetics, Inc. (FLGT) che segnala la proposta di vendita di 1.199 azioni ordinarie tramite Morgan Stanley Smith Barney il 27/08/2025 sul NASDAQ per un valore di mercato complessivo di $25.760,20. La comunicazione indica che le azioni da vendere sono state acquisite come azioni vincolate convertite in proprietà il 26/02/2024 come compenso in azioni, con 25.350 azioni inizialmente assegnate al titolare in quella data. L'emittente risulta avere 30.609.044 azioni in circolazione secondo l'avviso. Il dichiarante ha riportato più vendite in open market effettuate dalla stessa persona negli ultimi tre mesi per un totale di 3.704 azioni, con proventi lordi indicati in date specifiche. Il firmatario certifica l'assenza di informazioni materiali non divulgate e conferma le dichiarazioni richieste dalla Regola 144/10b5-1.
Presentación del Formulario 144 para Fulgent Genetics, Inc. (FLGT) que informa una propuesta de venta de 1.199 acciones ordinarias a través de Morgan Stanley Smith Barney el 27/08/2025 en NASDAQ por un valor de mercado agregado de $25.760,20. El registro indica que las acciones a vender se adquirieron como acciones restringidas que vencieron el 26/02/2024 como compensación en acciones, con 25.350 acciones originalmente emitidas al titular en esa fecha. El emisor tiene 30.609.044 acciones en circulación según el aviso. El declarante divulgó múltiples ventas anteriores en el mercado abierto por la misma persona en los últimos tres meses, por un total de 3.704 acciones, con ingresos brutos reportados en fechas específicas. El firmante certifica que no existe información material no divulgada y reconoce las representaciones de la Regla 144/10b5-1.
Fulgent Genetics, Inc. (FLGT)에 대한 Form 144 제출로 NASDAQ에서 Morgan Stanley Smith Barney를 통해 2025-08-27에 1,199주의 보통주 매도를 제안했으며 총 시가가 $25,760.20로 보고되었습니다. 제출서류에 따르면 매도 예정 주식은 2024-02-26에 성과한 제한주(베스팅된 주식)로 주식 보상으로 취득되었고, 해당일에 보유자에게 총 25,350주가 원래 부여되었습니다. 발행회사는 통지서 기준으로 30,609,044주의 발행주식수가 있습니다. 제출자는 동일 인물에 의한 지난 3개월 내 다수의 기존 공개시장 매도를 총 3,704주로 공개했으며 특정 날짜에 대한 총수익이 보고되었습니다. 서명자는 미공개 중대한 정보가 없음을 인증하고 Rule 144/10b5-1 진술을 확인합니다.
Déclaration du Formulaire 144 pour Fulgent Genetics, Inc. (FLGT) signalant une proposition de vente de 1 199 actions ordinaires via Morgan Stanley Smith Barney le 27/08/2025 sur le NASDAQ pour une valeur de marché totale de 25 760,20 $. Le dossier indique que les actions à vendre ont été acquises en tant que actions restreintes ayant acquis le droit (vested) le 26/02/2024 en tant que rémunération en actions, 25 350 actions ayant été initialement attribuées au titulaire à cette date. L'émetteur compte 30 609 044 actions en circulation selon l'avis. Le déclarant a divulgué plusieurs ventes antérieures sur le marché ouvert par la même personne au cours des trois derniers mois pour un total de 3 704 actions, avec des produits bruts rapportés à des dates précises. Le signataire certifie l'absence d'informations matérielles non divulguées et reconnaît les déclarations requises par la règle 144/10b5-1.
Einreichung von Formular 144 für Fulgent Genetics, Inc. (FLGT), die einen geplanten Verkauf von 1.199 Aktien des Stammkapitals über Morgan Stanley Smith Barney am 27.08.2025 an der NASDAQ mit einem Gesamtmarktwert von $25.760,20 meldet. Die Einreichung gibt an, dass die zu verkaufenden Aktien als Restricted Stock, die am 26.02.2024 vested wurden, als Aktienvergütung erworben wurden; dem Inhaber wurden an diesem Datum ursprünglich 25.350 Aktien zugeteilt. Der Emittent hat laut Mitteilung 30.609.044 ausstehende Aktien. Der Meldende gab mehrere frühere Verkäufe am offenen Markt derselben Person in den vergangenen drei Monaten mit einer Gesamtsumme von 3.704 Aktien an, wobei Bruttoerlöse zu bestimmten Daten ausgewiesen wurden. Der Unterzeichner bestätigt, dass keine nicht offengelegten wesentlichen Informationen vorliegen, und erkennt die Angaben gemäß Regel 144/10b5-1 an.
FAQ
What does the Form 144 filed for Fulgent Genetics (FLGT) disclose?
How were the shares being sold acquired according to the filing?
What is the number of shares outstanding reported in the Form 144 for FLGT?
Who is the broker handling the proposed sale in the Form 144?
Does the Form 144 state there is undisclosed material information?
